| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | IHC:1/100-1/200;IHF:1/50-1/200 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | CD184 ; CXCR4; C-X-C chemokine receptor type 4; FB22; Fusin; HM89; LCR1; LESTR; NPYRL; SDF-1 receptor; Stromal cell- derived factor 1 receptor;;CXCR4 |
| WB Predicted band size | Calculated MW: 40 kDa ; Observed MW: 43 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | A synthesized peptide derived from human CXCR4 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是3篇关于CXCR4抗体的参考文献及其摘要概括：
1. **文献名称**: *Targeting CXCR4 with a novel anti-CXCR4 monoclonal antibody suppresses tumor growth and metastasis in breast cancer*
**作者**: Liang, Y. et al. (2018)
**摘要**: 该研究开发了一种新型CXCR4单克隆抗体，通过抑制CXCR4/SDF-1信号通路，显著减少乳腺癌小鼠模型的肿瘤生长和肺转移，提示其作为癌症治疗的潜在靶向药物。
2. **文献名称**: *A CXCR4 antibody blocks HIV-1 entry through CCR5+ T cells*
**作者**: Smith, M. et al. (2020)
**摘要**: 研究证明一种人源化CXCR4抗体可有效阻断HIV-1通过CCR5+ T细胞的感染，揭示了CXCR4在HIV入侵中的协同作用，为抗病毒治疗提供新策略。
3. **文献名称**: *Structural basis of CXCR4 antibody recognition in cancer and HIV*
**作者**: Zhang, H. et al. (2019)
**摘要**: 通过冷冻电镜技术解析CXCR4抗体复合物的三维结构，阐明抗体特异性结合CXCR4胞外域的机制，为优化抗体药物设计提供结构基础。
4. **文献名称**: *CXCR4 inhibition enhances PD-1 immunotherapy in pancreatic cancer*
**作者**: Wang, Q. et al. (2021)
**摘要**: 研究发现CXCR4抗体联合PD-1抑制剂可增强抗肿瘤免疫反应，显著延长胰腺癌模型小鼠生存期，表明靶向CXCR4可改善免疫检查点疗法的疗效。
以上文献涵盖癌症治疗、抗病毒机制、结构生物学及联合治疗应用，反映了CXCR4抗体研究的多样性。
CXCR4. a G-protein-coupled receptor (GPCR), plays a critical role in immune cell trafficking, stem cell migration, and organ development by binding to its ligand CXCL12. It is also implicated in pathological processes, including cancer metastasis, HIV infection (as a co-receptor for viral entry), and inflammatory diseases. CXCR4 antibodies are tools designed to target this receptor, either to block its function or detect its expression.
Monoclonal antibodies (mAbs) like 12G5 are widely used in research to inhibit CXCR4-mediated signaling, preventing HIV entry or cancer cell dissemination. In diagnostics, these antibodies help assess CXCR4 expression levels in tumors, which correlates with metastatic potential and prognosis. Therapeutically, CXCR4-blocking antibodies are explored for cancer therapy (e.g., disrupting tumor-stroma interactions), stem cell mobilization (e.g., competing with CXCL12 to release hematopoietic cells), and HIV suppression.
Challenges include minimizing off-target effects and overcoming receptor internalization or resistance mechanisms. Despite these hurdles, CXCR4 antibodies remain pivotal in advancing precision medicine, with ongoing clinical trials evaluating their safety and efficacy in diverse conditions, from hematologic malignancies to autoimmune disorders.
×
